Citius Pharma sets sights on $675M merger deal njbiz.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from njbiz.com Daily Mail and Mail on Sunday newspapers.
Citius Pharmaceuticals, Inc. to receive $675 million in equity of Citius Oncology, Inc. and retain approximately 90% majority control in publicly listed Citius Oncology, Inc. post.
Global Cancer immunotherapy MKT to reach 152B by 2024 led by Astra Zeneca: AZN; Celgene: CELG Including Late Stage Newcomer; Citius Pharmaceuticals NASDAQ: CTXR
/PRNewswire/ Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development.
Citius Pharmaceuticals Inc. is realigning its management team to strengthen its commercial capabilities, the Cranford biopharmaceutical company announced April 13.